These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36840748)

  • 1. How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes.
    Hofbauer-Milan V; Fetzer S; Hagist C
    Pharmacoeconomics; 2023 May; 41(5):561-572. PubMed ID: 36840748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANALYSIS OF TRENDS IN LIFE EXPECTANCIES AND PER CAPITA GROSS DOMESTIC PRODUCT AS WELL AS PHARMACEUTICAL AND NON-PHARMACEUTICAL HEALTHCARE EXPENDITURES.
    Hermanowski T; Bystrov V; Staszewska-Bystrova A; Szafraniec-Buryło SI; Rabczenko D; Kolasa K; Orlewska E
    Acta Pol Pharm; 2015; 72(5):1045-50. PubMed ID: 26665412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projecting expenditure on medicines in the UK NHS.
    O'Neill P; Mestre-Ferrandiz J; Puig-Peiro R; Sussex J
    Pharmacoeconomics; 2013 Oct; 31(10):933-57. PubMed ID: 24037786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do drugs reduce utilisation of other healthcare resources?
    Crémieux PY; Ouellette P; Petit P
    Pharmacoeconomics; 2007; 25(3):209-21. PubMed ID: 17335307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare costs and obesity prevention: drug costs and other sector-specific consequences.
    Rappange DR; Brouwer WB; Hoogenveen RT; Van Baal PH
    Pharmacoeconomics; 2009; 27(12):1031-44. PubMed ID: 19908927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National trends in prescription drug expenditures and projections for 2021.
    Tichy EM; Hoffman JM; Suda KJ; Rim MH; Tadrous M; Cuellar S; Clark JS; Wiest MD; Matusiak LM; Schumock GT
    Am J Health Syst Pharm; 2021 Jul; 78(14):1294-1308. PubMed ID: 33880494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of newer drugs on health spending: do they really increase the costs?
    Civan A; Köksal B
    Health Econ; 2010 May; 19(5):581-95. PubMed ID: 19404925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.
    Moreno-Torres I; Puig-Junoy J; Raya JM
    Eur J Health Econ; 2011 Dec; 12(6):563-73. PubMed ID: 20809092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of proximity to death in modelling community medication expenditures for older people: evidence from New Zealand.
    Moore PV; Bennett K; Normand C
    Appl Health Econ Health Policy; 2014 Dec; 12(6):623-33. PubMed ID: 25141830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Life expectancy and health care expenditures: a new calculation for Germany using the costs of dying.
    Breyer F; Felder S
    Health Policy; 2006 Jan; 75(2):178-86. PubMed ID: 15893848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaco-economic impact of demographic change on pharmaceutical expenses in Germany and France.
    Boecking W; Klamar A; Kitzmann F; Kirch W
    BMC Public Health; 2012 Oct; 12():894. PubMed ID: 23092314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical expenditures as a correlate of population health in industrialized nations.
    Liu L; Cline RR; Schondelmeyer SW; Schommer JC
    Ann Pharmacother; 2008 Mar; 42(3):368-74. PubMed ID: 18272699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of factors affecting pharmaceutical expenditures.
    Mousnad MA; Shafie AA; Ibrahim MI
    Health Policy; 2014 Jun; 116(2-3):137-46. PubMed ID: 24726509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Spending in the United States and Other High-Income Countries.
    Papanicolas I; Woskie LR; Jha AK
    JAMA; 2018 Mar; 319(10):1024-1039. PubMed ID: 29536101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population aging and the determinants of healthcare expenditures: the case of hospital, medical and pharmaceutical care in british columbia, 1996 to 2006.
    Morgan S; Cunningham C
    Healthc Policy; 2011 Aug; 7(1):68-79. PubMed ID: 22851987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.